SCHEMBL24045477

SCHEMBL24045477

CCOC(O)C(F)(F)c1nc2cc(Cl)ccc2n1C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACSS2 Q9NR19 5/20 0.43
KMT2A Q03164 1/20 0.40
AGPAT2 O15120 1/20 0.36
BACE1 P56817 2/20 0.36
NUDT1 P36639 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HCRTR1 O43613 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16595231 0.76 LMNA (0.45) ACSS2KMT2AAGPAT2KDM4EALDH1A1
SCHEMBL17378554 0.76 KDM4E (0.45) ACSS2KMT2AAGPAT2BACE1NUDT1
SCHEMBL16595230 0.72 KDM4E (0.42) ACSS2KMT2AAGPAT2KDM4EALDH1A1
SCHEMBL20799418 0.72 AGPAT2 (0.47) ACSS2KMT2AAGPAT2BACE1KDM4E
SCHEMBL14504050 0.72 KDM4E (0.46) ACSS2KMT2AAGPAT2BACE1NUDT1
SCHEMBL17876423 0.66 KMT2A (0.49) KMT2ABACE1NUDT1KDM4EALDH1A1
SCHEMBL20670918 0.65 KMT2A (0.43) KMT2ABACE1NUDT1MAPTSMN1; SMN2
SCHEMBL17378563 0.65 RAB9A (0.45) ACSS2KMT2AKDM4EALDH1A1CYP1A2
SCHEMBL3988029 0.65 KMT2A (0.55) KMT2AAGPAT2BACE1NUDT1KDM4E
SCHEMBL16595229 0.64 LMNA (0.48) KMT2AAGPAT2KDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912977-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BioMarin Pharmaceutical Inc. (US) 2021-11-24 EP disclosed